scholarly journals A Selective Aldose Reductase Inhibitor of a New Structural Class Prevents or Reverses Early Retinal Abnormalities in Experimental Diabetic Retinopathy

Diabetes ◽  
2006 ◽  
Vol 55 (10) ◽  
pp. 2757-2762 ◽  
Author(s):  
W. Sun ◽  
P. J. Oates ◽  
J. B. Coutcher ◽  
C. Gerhardinger ◽  
M. Lorenzi
Keyword(s):  
Diabetic Retinopathy ◽  
Aldose Reductase ◽  
Reductase Inhibitor ◽  
Aldose Reductase Inhibitor ◽  
Structural Class

Electroretinogram in sucrose-fed diabetic rats treated with an aldose reductase inhibitor or an anticoagulant

1997 ◽  
Vol 273 (5) ◽  
pp. E965-E971 ◽  
Author(s):  
Nigishi Hotta ◽  
Jiro Nakamura ◽  
Fumihiko Sakakibara ◽  
Yoji Hamada ◽  
Tomohiro Hara ◽  
...  
Keyword(s):  
Animal Model ◽  
Diabetic Retinopathy ◽  
Aldose Reductase ◽  
Reductase Inhibitor ◽  
Polyol Pathway ◽  
Aldose Reductase Inhibitor ◽  
Dependent Diabetes Mellitus ◽  
Pathway Activity ◽  
Oletf Rats ◽  
Long Evans

To investigate the role of increased polyol pathway activity and hemodynamic deficits in the pathogenesis of diabetic retinopathy in non-insulin-dependent diabetes mellitus (NIDDM), Otsuka Long-Evans Tokushima fatty (OLETF) rats, an animal model of human NIDDM, were given water with or without 30% sucrose and some of them were fed laboratory chow containing 0.03% cilostazol, an anticoagulant, or 0.05% [5-(3-thienyl)tetrazol-1-yl] acetic acid monohydrate (TAT), an aldose reductase inhibitor, for 8 wk. Long-Evans Tokushima Otsuka (LETO) rats were used as nondiabetic controls. The peak latencies of oscillatory potentials of the electroretinogram in sucrose-fed OLETF rats were significantly prolonged compared with those in OLETF rats without sucrose feeding and LETO rats. There was a marked increase in platelet aggregability and a significant decrease in erythrocyte 2,3-diphosphoglycerate in sucrose-fed OLETF rats. Cilostazol significantly improved these parameters without changes in retinal levels of sorbitol and fructose. TAT, however, ameliorated all of these parameters. These findings confirm that the sucrose-fed OLETF rat is a useful animal model of retinopathy in human NIDDM and suggest that cilostazol improved diabetic retinopathy by modifying vascular factors, not by altering polyol pathway activity.

scholarly journals Effect of Ranirestat, a New Aldose Reductase Inhibitor, on Diabetic Retinopathy in SDT Rats

2014 ◽  
Vol 2014 ◽  
pp. 1-7 ◽  
Author(s):  
Fumihiko Toyoda ◽  
Yoshiaki Tanaka ◽  
Ayumi Ota ◽  
Machiko Shimmura ◽  
Nozomi Kinoshita ◽  
...  
Keyword(s):  
Diabetic Retinopathy ◽  
Aldose Reductase ◽  
Reductase Inhibitor ◽  
Retinal Thickness ◽  
Neuroprotective Effect ◽  
Treated Group ◽  
Aldose Reductase Inhibitor ◽  
Untreated Group ◽  
Sprague Dawley ◽  
Sprague Dawley Rats

Purpose. To evaluate the effect of ranirestat, a new aldose reductase inhibitor (ARI), on diabetic retinopathy (DR) in Spontaneously Diabetic Torii (SDT) rats.Methods. The animals were divided into six groups, normal Sprague-Dawley rats(n=8), untreated SDT rats(n=9), ranirestat-treated SDT rats (0.1, 1.0, and 10 mg/kg/day,n=7, 8, and 6, resp.), and epalrestat-treated SDT rats (100 mg/kg/day,n=7). Treated rats received oral ranirestat or epalrestat once daily for 40 weeks after the onset of diabetes. After the eyes were enucleated, the retinal thickness and the area of stained glial fibrillary acidic protein (GFAP) were measured.Results. The retinas in the untreated group were significantly thicker than those in the normal and ranirestat-treated (0.1, 1.0, and 10 mg/kg/day) groups. The immunostained area of GFAP in the untreated group was significantly larger than that in the normal and ranirestat-treated (1.0 and 10 mg/kg/day) groups. There were no significant differences between the untreated group and epalrestat-treated group in the retinal thickness and the area of stained GFAP.Conclusion. Ranirestat reduced the retinal thickness and the area of stained GFAP in SDT rats and might suppress DR and have a neuroprotective effect on diabetic retinas.

The effect of the aldose reductase inhibitor, ponalrestat, on the progression of diabetic retinopathy

1992 ◽  
Vol 6 (2) ◽  
pp. 131-137 ◽  
Author(s):  
Carlos Arauz-Pacheco ◽  
Luis C. Ramirez ◽  
Lourdes Pruneda ◽  
George E. Sanborn ◽  
Julio Rosenstock ◽  
...  
Keyword(s):  
Diabetic Retinopathy ◽  
Aldose Reductase ◽  
Reductase Inhibitor ◽  
Aldose Reductase Inhibitor

The effects of an aldose reductase inhibitor on the progression of diabetic retinopathy

1991 ◽  
Vol 78 (3-4) ◽  
pp. 153-159 ◽  
Author(s):  
A. Tromp ◽  
J. M. M. Hooymans ◽  
B. C. Barendsen ◽  
J. J. v. Doormaal
Keyword(s):  
Diabetic Retinopathy ◽  
Aldose Reductase ◽  
Reductase Inhibitor ◽  
Aldose Reductase Inhibitor

186-OR: Safety and Tolerability of the Next Generation Aldose Reductase Inhibitor (ARI) AT-001 Supports Initiation of the Pivotal Trial in Diabetic Cardiomyopathy (DbCM)

Diabetes ◽  
2020 ◽  
Vol 69 (Supplement 1) ◽  
pp. 186-OR
Author(s):  
RICCARDO PERFETTI ◽  
FRANCESCA C. LAWSON ◽  
JULIO ROSENSTOCK ◽  
JAMES JANUZZI ◽  
SHOSHANA SHENDELMAN ◽  
...  
Keyword(s):  
Aldose Reductase ◽  
Diabetic Cardiomyopathy ◽  
Reductase Inhibitor ◽  
Aldose Reductase Inhibitor ◽  
Pivotal Trial ◽  
Next Generation

462-P: AT-001, a Next Generation Aldose Reductase Inhibitor with Improved Selectivity and Specificity, Protects from Cellular Damage Associated with Hyperglycemia

Diabetes ◽  
2020 ◽  
Vol 69 (Supplement 1) ◽  
pp. 462-P
Author(s):  
RICCARDO PERFETTI ◽  
GAUTHAM YEPURI ◽  
NOSIRUDEEN A. QUADRI ◽  
RAVICHANDRAN RAMASAMY ◽  
AMEEN F. GHANNAM ◽  
...  
Keyword(s):  
Aldose Reductase ◽  
Reductase Inhibitor ◽  
Aldose Reductase Inhibitor ◽  
Cellular Damage ◽  
Next Generation
Sign in / Sign up

Export Citation Format

Share Document